Bone Biologics (BBLG) Stock Price, News & Analysis

Company Overview

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $4.70 to $5.33
• 50-Day Range: $3.96 to $5.56
• 52-Week Range: $3.42 to $25.50
• Volume: 36,919 shs
• Average Volume: 32,215 shs
• Market Capitalization: $15.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BBLG Stock Analysis - Frequently Asked Questions

How have BBLG shares performed this year?

Bone Biologics' stock was trading at $5.6418 at the beginning of 2025. Since then, BBLG shares have decreased by 15.5% and is now trading at $4.77.
View the best growth stocks for 2025 here.

How were Bone Biologics' earnings last quarter?

Bone Biologics Co. (OTC:BBLG) announced its quarterly earnings results on Monday, August, 14th. The company reported ($10.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($9.00) by $1.14.

When did Bone Biologics' stock split?

Shares of Bone Biologics reverse split before market open on Tuesday, June 10th 2025. The 1-6 reverse split was announced on Monday, June 9th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of Bone Biologics?

Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bone Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bone Biologics investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Cisco Systems (CSCO).

Company Calendar

• Last Earnings: 8/14/2023
• Today: 6/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTC
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: Medical Equipment
• Current Symbol: OTC:BBLG
• CIK: 1419554
• Web: www.bonebiologics.com
• Phone: 781-552-4452
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($49.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -123.44%
• Return on Assets: -82.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.95
• Quick Ratio: 3.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.82 per share
• Price / Book: 2.62

Miscellaneous

• Outstanding Shares: 3,271,000
• Free Float: 2,886,000
• Market Cap: $15.60 million
• Optionable: Not Optionable
• Beta: 0.75